Target intelligence / Profile preview

26S proteasome non-ATPase regulatory subunit 4 (PSMD4) (PSMD4)

Target
PSMD4
Molecular classification
Proteasome subunit, Ubiquitin-binding protein, Regulatory protein
01

Overview

26S proteasome non-ATPase regulatory subunit 4 (PSMD4), also known as Rpn10 or S5a, is a key ubiquitin receptor within the 19S regulatory particle of the 26S proteasome (UniProt P55036). It functions by recognizing and binding polyubiquitinated proteins through its ubiquitin-interacting motifs (UIMs), facilitating their delivery to the catalytic core for degradation (PubMed: 10490618). PSMD4 is essential for maintaining cellular protein homeostasis, and its dysregulation is linked to various cancers, most notably multiple myeloma and hepatocellular carcinoma, where its overexpression correlates with poor prognosis and resistance to conventional proteasome inhibitors (PubMed: 28416776, 31110014). Targeting PSMD4 mRNA using RNA interference (RNAi) or antisense oligonucleotides (ASOs) is an emerging therapeutic approach designed to deplete the protein and disrupt the ubiquitin-proteasome system in malignant cells (PubMed: 16123311). This strategy aims to induce proteotoxic stress and subsequent apoptosis in cancer cells that are heavily reliant on efficient protein clearance. While promising, the therapeutic application of PSMD4-targeting agents faces challenges such as achieving efficient delivery to tumor sites and minimizing systemic toxicity associated with broad proteasome inhibition (PubMed: 25635005).

Other names
Rpn10S5aMCB1P54AFAF-1ANGELp54Proteasome 26S subunit, non-ATPase 4
02

Mechanism of action

RNA interference or antisense-mediated degradation of PSMD4 mRNA, leading to reduced PSMD4 protein levels and subsequent inhibition of ubiquitin-dependent protein degradation.

03

Biological functions

Protein degradationUbiquitin-dependent proteolysisProteasome assemblyProtein homeostasis
04

Disease associations

Multiple myelomaHepatocellular carcinomaBreast cancerNeurodegenerative disease
05

Safety considerations

Systemic proteotoxicityPeripheral neuropathyOff-target effects on essential protein turnoverPotential for compensatory upregulation of other ubiquitin receptors
06

Interacting drugs

Experimental antisense oligonucleotides

1 more in the full profile.

07

Biomarkers

PSMD4 mRNA expression levelsPSMD4 protein expression levelsAccumulation of polyubiquitinated proteins

Beyond the preview

Go deeper on 26S proteasome non-ATPase regulatory subunit 4 (PSMD4) (PSMD4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 4 (PSMD4) (PSMD4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call